Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis - PubMed (original) (raw)
Review
. 2009 Jul 2;61(7-8):554-71.
doi: 10.1016/j.addr.2009.03.013. Epub 2009 Apr 23.
Affiliations
- PMID: 19394376
- DOI: 10.1016/j.addr.2009.03.013
Review
Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis
Dominik E Dorer et al. Adv Drug Deliv Rev. 2009.
Abstract
Cancer-specificity is the key requirement for a drug or treatment regimen to be effective against malignant disease--and has rarely been achieved adequately to date. Therefore, targeting strategies need to be implemented for future therapies to ensure efficient activity at the site of patients' tumors or metastases without causing intolerable side-effects. Gene therapy and viral oncolysis represent treatment modalities that offer unique opportunities for tumor targeting. This is because both the transfer of genes with anti-cancer activity and viral replication-induced cell killing, respectively, facilitate the incorporation of multiple mechanisms restricting their activity to cancer. To this end, cellular mechanisms of gene regulation have been successfully exploited to direct therapeutic gene expression and viral cell lysis to cancer cells. Here, transcriptional targeting has been the role model and most widely investigated. This approach exploits cellular gene regulatory elements that mediate cell type-specific transcription to restrict the expression of therapeutic genes or essential viral genes, ideally to cancer cells. In this review, we first discuss the rationale for such promoter targeting and its limitations. We then give an overview how tissue-/tumor-specific promoters are being identified and characterized. Strategies to apply and optimize such promoters for the engineering of targeted viral gene transfer vectors and oncolytic viruses-with respect to promoter size, selectivity and activity in the context of viral genomes-are described. Finally, we discuss in more detail individual examples for transcriptionally targeted virus drugs. First highlighting oncolytic viruses targeted by prostate-specific promoters and by the telomerase promoter as representatives of tissue-targeted and pan-cancer-specific virus drugs respectively, and secondly recent developments of the last two years.
Similar articles
- Adenovirus-mediated cancer gene therapy and virotherapy (Review).
Fukazawa T, Matsuoka J, Yamatsuji T, Maeda Y, Durbin ML, Naomoto Y. Fukazawa T, et al. Int J Mol Med. 2010 Jan;25(1):3-10. Int J Mol Med. 2010. PMID: 19956895 Review. - Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.
Thorne SH, Hermiston T, Kirn D. Thorne SH, et al. Semin Oncol. 2005 Dec;32(6):537-48. doi: 10.1053/j.seminoncol.2005.09.007. Semin Oncol. 2005. PMID: 16338419 Review. - Targeting gene-virotherapy of cancer.
Liu XY, Gu JF. Liu XY, et al. Cell Res. 2006 Jan;16(1):25-30. doi: 10.1038/sj.cr.7310005. Cell Res. 2006. PMID: 16467873 Retracted. Review. - Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.
Lu Y. Lu Y. Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):572-88. doi: 10.1016/j.addr.2009.03.014. Epub 2009 Apr 23. Adv Drug Deliv Rev. 2009. PMID: 19393705 Review. - Viral gene therapy strategies: from basic science to clinical application.
Young LS, Searle PF, Onion D, Mautner V. Young LS, et al. J Pathol. 2006 Jan;208(2):299-318. doi: 10.1002/path.1896. J Pathol. 2006. PMID: 16362990 Review.
Cited by
- Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.
Zhu B, Yin H, Zhang D, Zhang M, Chao X, Scimeca L, Wu MR. Zhu B, et al. Cell Mol Immunol. 2024 May;21(5):436-447. doi: 10.1038/s41423-024-01153-x. Epub 2024 Apr 11. Cell Mol Immunol. 2024. PMID: 38605087 Free PMC article. Review. - Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer.
Nia GE, Nikpayam E, Farrokhi M, Bolhassani A, Meuwissen R. Nia GE, et al. Mol Ther Oncol. 2024 Feb 29;32(1):200788. doi: 10.1016/j.omton.2024.200788. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596310 Free PMC article. Review. - Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
Chen L, Zuo M, Zhou Q, Wang Y. Chen L, et al. Front Immunol. 2023 Dec 15;14:1308890. doi: 10.3389/fimmu.2023.1308890. eCollection 2023. Front Immunol. 2023. PMID: 38169820 Free PMC article. Review. - Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy.
El-Sayed ASA, Mohamed NZ, Yassin MA, Amer MM, El-Sharkawy R, El-Sayed N, Ali MG. El-Sayed ASA, et al. Heliyon. 2022 Sep 16;8(9):e10660. doi: 10.1016/j.heliyon.2022.e10660. eCollection 2022 Sep. Heliyon. 2022. PMID: 36164544 Free PMC article. Review. - Repurposing antifungal drugs for cancer therapy.
Weng N, Zhang Z, Tan Y, Zhang X, Wei X, Zhu Q. Weng N, et al. J Adv Res. 2023 Jun;48:259-273. doi: 10.1016/j.jare.2022.08.018. Epub 2022 Sep 5. J Adv Res. 2023. PMID: 36067975 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical